Delivering meaningful growth

July 30, 2026 – After 5:45pm CET
Regulated information

Half-year Report 2026
Substantial progress including portfolio simplification, investments in controlled and co-controlled assets, and attractive shareholder returns

- **Good progress on disposals**
- **Three new investments in controlled or co-controlled assets, totaling €2.3bn[1]**
- **Value creation of €130m[2] from direct private assets**
- **Increased dividend per share of €5.125[3] and ongoing share buybacks and cancellations**
- **TSR of 17.5%[4] and NAV per share of €100.77**
- **Liquidity of €4.6bn and Loan To Value of 0.0% to support future transactions**

GBL's Half-year Report 2026 was published today and is accessible via this link.

GBL achieved several milestones in simplifying the portfolio, focusing on direct private assets, and delivering attractive shareholder returns.

The group has, in particular,: (i) reduced its exposure to listed and non-core asset classes, resulting in more than €5bn of total disposals[5], (ii) invested €2.3bn[1] in controlled and co-controlled assets and generated €130m[2] of value uplift from direct private assets, and (iii) delivered €773m of cash returns, composed of a higher dividend per share and share buybacks.

GBL cancelled 3.4m shares at the Annual Shareholders' Meeting in May, thereby supporting the net asset value per share.

With liquidity of €4.6bn and a Loan To Value of 0.0%, GBL has firepower to pursue compelling investment opportunities.

As previously communicated, the group intends to maintain the dividend per share at the current increased level for the foreseeable future and pursue share buybacks opportunistically.

Investors are invited to read the full Half-year Report 2026 for a more complete description of GBL's activities and performance. The Half-year Report 2026 also includes the main risk factors related to GBL and its participations.

---

1 The acquisition of a co-controlling stake in Rayner, an ophthalmic MedTech specialist, closed on May 28, 2026; the acquisition of a controlling stake in BUKO Group, a leading platform in temporary traffic management, closed on July 8, 2026; the voluntary cash tender offer of Recordati, the specialized pharmaceutical company, was jointly announced with CVC Capital Partners Fund IX on May 22, 2026 and is subject to customary regulatory approvals – please refer to the May 22, 2026 press release

2 Affidea (+ €29m), Sanoptis (+ €103m), Rayner (N/A), Canyon (+ €1m), Voodoo (+ €6m) and Parques Reunidos (- €9m)

3 For FY 2025; paid as from May 18, 2026

4 June 30, 2025 to June 30, 2026

5 The sum of disposals of (i) adidas (€1.7bn) in 2024, (ii) GBL Capital (€1.7bn), SGS (€0.8bn), and Umicore (€0.3bn) in 2025 and (iii) Umicore (€0.3bn), Concentrix (€0.1bn) and non-core asset classes (€0.2bn) in H1 2026

For more information

Xavier Likin
Chief Financial Officer
Tel: + 32 2 289 17 72
xlikin@gbl.com

Alison Donohoe
Head of Investor Relations
Tel : +32 2 289 17 64
adonohoe@gbl.com

About Groupe Bruxelles Lambert

Groupe Bruxelles Lambert ("GBL") is an established investment holding company, with over seventy years of stock exchange listing and a net asset value of €13.1bn at the end of June 2026. As a leading and active investor in Europe, GBL focuses on long-term value creation with the support of a stable family shareholder base.

GBL is focused on *delivering meaningful growth* by providing attractive returns to its shareholders through a combination of growth in its net asset value per share, a sustainable dividend and share buybacks.

GBL is listed on Euronext Brussels (Ticker: GBLB BB; ISIN code: BE0003797140) and is included in the BEL20 index.